首页 > 最新文献

Cancer Biology & Medicine最新文献

英文 中文
Unraveling vascular mechanisms in melanoma: roles of angiogenesis and vasculogenic mimicry in tumor progression and therapeutic resistance. 揭示黑色素瘤的血管机制:血管生成和血管生成模拟在肿瘤进展和治疗抵抗中的作用。
IF 8.4 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-17 DOI: 10.20892/j.issn.2095-3941.2025.0048
Simona Serratì, Lucia Raho, Gisella De Giosa, Letizia Porcelli, Roberta Di Fonte, Rossella Fasano, Pedro Miguel Lacal, Grazia Graziani, Rosa Maria Iacobazzi, Amalia Azzariti

Melanoma, the most aggressive form of skin cancer, remains a significant clinical challenge due to the high metastatic potential and drug resistance. This review explores the pivotal roles of angiogenesis and vasculogenic mimicry in melanoma progression and treatment resistance. Angiogenesis, driven primarily by VEGF/VEGFR signaling, is critical for tumor sustenance but is often insufficient under hypoxic conditions, prompting melanoma cells to adapt by forming vascular-like structures (i.e., vasculogenic mimicry). These structures enable melanoma cells to mimic endothelial functions and are linked to increased metastasis and poor prognosis. Molecular drivers, including VE-cadherin, EphA2, and hypoxia-inducible factors, have been identified as key regulators of these processes. Current anti-angiogenic agents have limited efficacy in advanced/metastatic melanoma due to tumor plasticity and the interplay between angiogenesis and vasculogenic mimicry. The review highlights the need for therapeutic strategies targeting both mechanisms, emphasizing the importance of combination treatments to overcome resistance. Future research should aim to elucidate the molecular underpinnings of angiogenesis and vasculogenic mimicry to improve melanoma management and patient outcomes.

黑色素瘤是最具侵袭性的皮肤癌,由于其高转移潜力和耐药性,仍然是一个重大的临床挑战。本文综述了血管生成和血管生成模拟在黑色素瘤进展和治疗抵抗中的关键作用。血管生成主要由VEGF/VEGFR信号驱动,对肿瘤维持至关重要,但在缺氧条件下往往不足,促使黑色素瘤细胞通过形成血管样结构(即血管生成模仿)来适应。这些结构使黑色素瘤细胞能够模仿内皮细胞的功能,并与转移增加和预后不良有关。包括VE-cadherin、EphA2和缺氧诱导因子在内的分子驱动因子已被确定为这些过程的关键调节因子。由于肿瘤的可塑性以及血管生成和血管生成模拟之间的相互作用,目前的抗血管生成药物对晚期/转移性黑色素瘤的疗效有限。这篇综述强调了针对这两种机制的治疗策略的必要性,强调了联合治疗克服耐药性的重要性。未来的研究应旨在阐明血管生成和血管生成模拟的分子基础,以改善黑色素瘤的管理和患者的预后。
{"title":"Unraveling vascular mechanisms in melanoma: roles of angiogenesis and vasculogenic mimicry in tumor progression and therapeutic resistance.","authors":"Simona Serratì, Lucia Raho, Gisella De Giosa, Letizia Porcelli, Roberta Di Fonte, Rossella Fasano, Pedro Miguel Lacal, Grazia Graziani, Rosa Maria Iacobazzi, Amalia Azzariti","doi":"10.20892/j.issn.2095-3941.2025.0048","DOIUrl":"10.20892/j.issn.2095-3941.2025.0048","url":null,"abstract":"<p><p>Melanoma, the most aggressive form of skin cancer, remains a significant clinical challenge due to the high metastatic potential and drug resistance. This review explores the pivotal roles of angiogenesis and vasculogenic mimicry in melanoma progression and treatment resistance. Angiogenesis, driven primarily by VEGF/VEGFR signaling, is critical for tumor sustenance but is often insufficient under hypoxic conditions, prompting melanoma cells to adapt by forming vascular-like structures (i.e., vasculogenic mimicry). These structures enable melanoma cells to mimic endothelial functions and are linked to increased metastasis and poor prognosis. Molecular drivers, including VE-cadherin, EphA2, and hypoxia-inducible factors, have been identified as key regulators of these processes. Current anti-angiogenic agents have limited efficacy in advanced/metastatic melanoma due to tumor plasticity and the interplay between angiogenesis and vasculogenic mimicry. The review highlights the need for therapeutic strategies targeting both mechanisms, emphasizing the importance of combination treatments to overcome resistance. Future research should aim to elucidate the molecular underpinnings of angiogenesis and vasculogenic mimicry to improve melanoma management and patient outcomes.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"22 11","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12624814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145539064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chidamide suppresses macrophage-mediated immune evasion and tumor progression in small cell lung cancer by targeting the STAT4/CCL2 signaling pathway. 奇达胺通过靶向STAT4/CCL2信号通路抑制小细胞肺癌巨噬细胞介导的免疫逃避和肿瘤进展。
IF 8.4 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-10-23 DOI: 10.20892/j.issn.2095-3941.2024.0241
Wenting Liu, Ting Mei, Yantao Jiang, Jingya Wang, Mengjie Li, Liuchun Wang, Zhaoting Meng, Tingting Qin, Dingzhi Huang

Objective: This study aimed at exploring the effects of the epigenetic regulator, chidamide, on reprogramming the immunosuppressive tumor microenvironment in small cell lung cancer (SCLC), particularly the roles in macrophage polarization and angiogenesis. The therapeutic efficacy of combining chidamide with the anti-angiogenic agent, anlotinib, for refractory SCLC was also evaluated.

Methods: RNA sequencing and functional validation were performed to assess chidamide's effects on macrophages. Signal transducer and activator of transcription 4 (STAT4)-mediated transcriptional activation of CCL2 was confirmed with ChIP-qPCR. The synergistic efficacy of chidamide in combination with anlotinib was tested in preclinical models.

Results: Chidamide enhanced macrophage infiltration and induced macrophage polarization toward the anti-tumor M1 phenotype. Mechanistically, chidamide upregulated CCL2 via STAT4 transcriptional activation, thereby reshaping the tumor immune microenvironment (TIME). Combining chidamide with anlotinib synergistically suppressed tumor growth and remodeled the immunosuppressive TME in SCLC in vivo.

Conclusions: Chidamide reshaped the SCLC TIME by activating STAT4/CCL2, thus driving M1 macrophage polarization and enhancing anti-tumor immunity. Our findings highlight coordinated TIME-targeted therapy as a translatable strategy to overcome therapeutic resistance in SCLC and provide a rationale for clinical trials examining epigenetic and anti-angiogenic therapeutics combinations.

目的:探讨表观遗传调控因子奇达胺对小细胞肺癌(SCLC)免疫抑制肿瘤微环境重编程的影响,特别是在巨噬细胞极化和血管生成中的作用。同时评价了奇达胺联合抗血管生成药物安洛替尼治疗难治性SCLC的疗效。方法:采用RNA测序和功能验证方法评价奇达胺对巨噬细胞的作用。用ChIP-qPCR证实了STAT4介导的CCL2的转录激活。在临床前模型中测试了奇达胺与安洛替尼联合使用的协同效应。结果:奇达胺增强巨噬细胞浸润,诱导巨噬细胞向抗肿瘤M1表型极化。在机制上,奇达胺通过STAT4转录激活上调CCL2,从而重塑肿瘤免疫微环境(TIME)。奇达胺联合安洛替尼在体内协同抑制SCLC肿瘤生长,重塑免疫抑制性TME。结论:奇达胺通过激活STAT4/CCL2重塑SCLC TIME,从而驱动M1巨噬细胞极化,增强抗肿瘤免疫。我们的研究结果强调了协调时间靶向治疗作为克服SCLC治疗耐药的可翻译策略,并为临床试验检查表观遗传和抗血管生成治疗组合提供了理论依据。
{"title":"Chidamide suppresses macrophage-mediated immune evasion and tumor progression in small cell lung cancer by targeting the STAT4/CCL2 signaling pathway.","authors":"Wenting Liu, Ting Mei, Yantao Jiang, Jingya Wang, Mengjie Li, Liuchun Wang, Zhaoting Meng, Tingting Qin, Dingzhi Huang","doi":"10.20892/j.issn.2095-3941.2024.0241","DOIUrl":"10.20892/j.issn.2095-3941.2024.0241","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed at exploring the effects of the epigenetic regulator, chidamide, on reprogramming the immunosuppressive tumor microenvironment in small cell lung cancer (SCLC), particularly the roles in macrophage polarization and angiogenesis. The therapeutic efficacy of combining chidamide with the anti-angiogenic agent, anlotinib, for refractory SCLC was also evaluated.</p><p><strong>Methods: </strong>RNA sequencing and functional validation were performed to assess chidamide's effects on macrophages. Signal transducer and activator of transcription 4 (STAT4)-mediated transcriptional activation of CCL2 was confirmed with ChIP-qPCR. The synergistic efficacy of chidamide in combination with anlotinib was tested in preclinical models.</p><p><strong>Results: </strong>Chidamide enhanced macrophage infiltration and induced macrophage polarization toward the anti-tumor M1 phenotype. Mechanistically, chidamide upregulated CCL2 <i>via</i> STAT4 transcriptional activation, thereby reshaping the tumor immune microenvironment (TIME). Combining chidamide with anlotinib synergistically suppressed tumor growth and remodeled the immunosuppressive TME in SCLC <i>in vivo</i>.</p><p><strong>Conclusions: </strong>Chidamide reshaped the SCLC TIME by activating STAT4/CCL2, thus driving M1 macrophage polarization and enhancing anti-tumor immunity. Our findings highlight coordinated TIME-targeted therapy as a translatable strategy to overcome therapeutic resistance in SCLC and provide a rationale for clinical trials examining epigenetic and anti-angiogenic therapeutics combinations.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12724304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145353852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive investigation of the molecular basis of cancer dependencies suggests therapeutic options for breast cancer. 对癌症依赖的分子基础的全面研究为乳腺癌的治疗选择提供了建议。
IF 8.4 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-10-23 DOI: 10.20892/j.issn.2095-3941.2025.0290
Rui Ding, Zhiming Shao, Tianjian Yu

Objective: Large-scale CRISPR screens have identified essential genes across cancer cell lines, but links between tumor functional properties and specific dependencies require investigation to reveal the mechanisms underlying dependencies and broaden understanding of targeted therapy.

Methods: We selected 47 breast cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE) with multi-omics data including gene dependency; somatic mutations; copy number alterations; and transcriptomic, proteomic, metabolomic, and methylation data. We established a dependency marker association (DMA) analytic pipeline by using linear regression modeling to assess associations between 3,874 representative gene dependencies and multi-omics markers. Additionally, we conducted non-negative matrix factorization clustering, to stratify breast cancer cell lines according to gene dependency features, and investigated cluster-specific DMAs.

Results: We interpreted valuable DMAs according to two primary aspects. First, dependencies associated with gain-of-function alterations revealed addiction to lactate transporter SLC16A3, thus suggesting a promising therapeutic target. Second, dependencies associated with loss-of-function alterations included synthetic lethality (SL), collateral SL, and prioritized metabolic SL, encompassing paralog SL (e.g., IMPDH1 and IMPDH2), single pathway SL (e.g., GFPT1 and UAP1), and alternative pathway SL (e.g., GPI and PGD). DMA analysis of the two clusters with divergent dependency signatures demonstrated that cluster1 cell lines exhibited extensive metabolism with mitochondrial protein dependencies, whereas cluster2 displays enhanced cell signaling, and reliance on DNA replication and membrane organelle regulators.

Conclusions: We established a DMA analysis pipeline linking the gene dependencies of breast cancer cell lines to multi-omics characteristics, thus elucidating the underpinnings of tumor dependencies and offering a valuable resource for developing novel precision treatment strategies incorporating relevant markers.

目的:大规模的CRISPR筛选已经确定了跨越癌细胞系的必要基因,但肿瘤功能特性与特定依赖之间的联系需要研究,以揭示依赖的潜在机制,并拓宽对靶向治疗的理解。方法:从美国癌症细胞系百科全书(cancer cell Line Encyclopedia, CCLE)中选取47株乳腺癌细胞系,其中包含多组学数据,包括基因依赖性;体细胞突变;副本号码更改;转录组学、蛋白质组学、代谢组学和甲基化数据。我们利用线性回归模型建立了依赖标记关联(DMA)分析管道,评估了3874个具有代表性的基因依赖与多组学标记之间的关联。此外,我们进行了非阴性基质因子聚类,根据基因依赖特征对乳腺癌细胞系进行分层,并研究了簇特异性DMAs。结果:我们从两个主要方面解释了有价值的dma。首先,与功能获得改变相关的依赖性揭示了对乳酸转运蛋白SLC16A3的依赖性,从而提示了一个有希望的治疗靶点。其次,与功能丧失改变相关的依赖性包括合成致死率(SL)、侧支SL和优先代谢SL,包括平行SL(例如,IMPDH1和IMPDH2)、单途径SL(例如,GFPT1和UAP1)和替代途径SL(例如,GPI和PGD)。对具有不同依赖特征的两个集群的DMA分析表明,cluster1细胞系表现出广泛的线粒体蛋白依赖代谢,而cluster2细胞系表现出增强的细胞信号传导,并依赖DNA复制和膜细胞器调节因子。结论:我们建立了将乳腺癌细胞系的基因依赖性与多组学特征联系起来的DMA分析管道,从而阐明了肿瘤依赖性的基础,并为开发包含相关标记的新型精准治疗策略提供了宝贵的资源。
{"title":"Comprehensive investigation of the molecular basis of cancer dependencies suggests therapeutic options for breast cancer.","authors":"Rui Ding, Zhiming Shao, Tianjian Yu","doi":"10.20892/j.issn.2095-3941.2025.0290","DOIUrl":"10.20892/j.issn.2095-3941.2025.0290","url":null,"abstract":"<p><strong>Objective: </strong>Large-scale CRISPR screens have identified essential genes across cancer cell lines, but links between tumor functional properties and specific dependencies require investigation to reveal the mechanisms underlying dependencies and broaden understanding of targeted therapy.</p><p><strong>Methods: </strong>We selected 47 breast cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE) with multi-omics data including gene dependency; somatic mutations; copy number alterations; and transcriptomic, proteomic, metabolomic, and methylation data. We established a dependency marker association (DMA) analytic pipeline by using linear regression modeling to assess associations between 3,874 representative gene dependencies and multi-omics markers. Additionally, we conducted non-negative matrix factorization clustering, to stratify breast cancer cell lines according to gene dependency features, and investigated cluster-specific DMAs.</p><p><strong>Results: </strong>We interpreted valuable DMAs according to two primary aspects. First, dependencies associated with gain-of-function alterations revealed addiction to lactate transporter SLC16A3, thus suggesting a promising therapeutic target. Second, dependencies associated with loss-of-function alterations included synthetic lethality (SL), collateral SL, and prioritized metabolic SL, encompassing paralog SL (e.g., IMPDH1 and IMPDH2), single pathway SL (e.g., GFPT1 and UAP1), and alternative pathway SL (e.g., GPI and PGD). DMA analysis of the two clusters with divergent dependency signatures demonstrated that cluster1 cell lines exhibited extensive metabolism with mitochondrial protein dependencies, whereas cluster2 displays enhanced cell signaling, and reliance on DNA replication and membrane organelle regulators.</p><p><strong>Conclusions: </strong>We established a DMA analysis pipeline linking the gene dependencies of breast cancer cell lines to multi-omics characteristics, thus elucidating the underpinnings of tumor dependencies and offering a valuable resource for developing novel precision treatment strategies incorporating relevant markers.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12724301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145353925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COX-2 inhibition synergizes with radioimmunotherapy by promoting TCF1+CD8+ T cell infiltration in NSCLC. COX-2抑制通过促进非小细胞肺癌TCF1+CD8+ T细胞浸润与放射免疫治疗协同作用。
IF 8.4 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-10-22 DOI: 10.20892/j.issn.2095-3941.2025.0205
Lin Ma, Menglin Bai, Yao Wang, Xueying Zhai, Jinming Yu, Xiangjiao Meng
{"title":"COX-2 inhibition synergizes with radioimmunotherapy by promoting TCF1<sup>+</sup>CD8<sup>+</sup> T cell infiltration in NSCLC.","authors":"Lin Ma, Menglin Bai, Yao Wang, Xueying Zhai, Jinming Yu, Xiangjiao Meng","doi":"10.20892/j.issn.2095-3941.2025.0205","DOIUrl":"10.20892/j.issn.2095-3941.2025.0205","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12724291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145343572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase I clinical study of humanized BCMA-single-domain antibodies targeting CAR-T in patients with relapsed or refractory multiple myeloma. 靶向CAR-T的人源化bcma单域抗体在复发或难治性多发性骨髓瘤患者中的I期临床研究
IF 8.4 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-10-17 DOI: 10.20892/j.issn.2095-3941.2024.0581
Gaofeng Zheng, Ruyi Xu, Heng Mei, Xiaoyan Han, Donghua He, Yanling Weng, Cheng Wen, Zhuoxiao Cao, Zhen Cai
{"title":"Phase I clinical study of humanized BCMA-single-domain antibodies targeting CAR-T in patients with relapsed or refractory multiple myeloma.","authors":"Gaofeng Zheng, Ruyi Xu, Heng Mei, Xiaoyan Han, Donghua He, Yanling Weng, Cheng Wen, Zhuoxiao Cao, Zhen Cai","doi":"10.20892/j.issn.2095-3941.2024.0581","DOIUrl":"10.20892/j.issn.2095-3941.2024.0581","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12624805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145336479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying occult high-risk features and stratified management strategies following curative resection for ampullary adenocarcinoma. 壶腹腺癌根治性切除后的潜在高危特征及分层处理策略。
IF 8.4 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-10-16 DOI: 10.20892/j.issn.2095-3941.2025.0181
Xiaoqing Ma, Chenyang Meng, Xuejing Shi, Zhaoyu Zhang, Qiuli Li, Hongwei Wang, Yuexiang Liang, Song Gao, Xiuchao Wang, Chuntao Gao, Jian Wang, Weidong Ma, Yukuan Feng, Shuo Li, Xingyun Chen, Wei Li, Shangheng Shi, Tianxing Zhou, Jun Yu, Jihui Hao

Objective: The aim of the current study was to identify independent prognostic factors, evaluate differential adjuvant chemotherapy efficacy across clinicopathologic subgroups, and define adjuvant chemotherapy-sensitive populations.

Methods: A retrospective analysis of 168 AAC patients undergoing curative pancreaticoduodenectomy (2011-2020) was performed. Cases were classified into intestinal (28.0%), pancreatobiliary (30.4%), and mixed subtypes (18.5%) per NCCN (v2.2025) criteria. Independent prognostic factors for AAC patients were identified through uni- and multi-variable Cox proportional hazards modeling and subgroup analyses were stratified by age range, gender, differentiation, T stage, N stage, BVI, TDs, and PNI.

Results: The pancreatobiliary signature (HR = 2.884, P < 0.001) and BVI (HR = 2.330, P = 0.001) were independent poor prognostic factors. Adjuvant chemotherapy improved overall survival (OS) in the following AAC patients: T3-T4 stage (HR = 0.485, P = 0.050); N1-N2 stage (HR = 0.365, P = 0.008); and TD-positive (HR = 0.401, P = 0.026). The median OS increased from 22.3-51.3 months with adjuvant chemotherapy in TD-positive patients (P = 0.019). TD positivity conferred a worse prognosis in BVI-negative subgroups (OS: HR = 3.840, 95% CI: 2.058-7.166, P < 0.001; and progression-free survival (PFS): HR = 2.950, 95% CI: 1.550-5.617, P = 0.002).

Conclusions: The pancreatobiliary signature and BVI constitute critical high-risk pathologic features in AAC. TD status identified high-risk cohorts, thus enabling postoperative risk-stratified treatment strategies. In patients negative for pancreatobiliary signature or BVI, TD positivity predicted significantly worse survival.

目的:本研究的目的是确定独立的预后因素,评估不同临床病理亚组的辅助化疗疗效,并确定辅助化疗敏感人群。方法:对2011-2020年行根治性胰十二指肠切除术的168例AAC患者进行回顾性分析。根据NCCN (v2.2025)标准,病例分为肠道(28.0%)、胰胆道(30.4%)和混合亚型(18.5%)。通过单变量和多变量Cox比例风险模型确定AAC患者的独立预后因素,并按年龄范围、性别、分化、T分期、N分期、BVI、TDs和PNI进行亚组分析。结果:胰胆管特征(HR = 2.884, P < 0.001)和BVI (HR = 2.330, P = 0.001)是独立的不良预后因素。辅助化疗提高了以下AAC患者的总生存期(OS): T3-T4期(HR = 0.485, P = 0.050);N1-N2期(HR = 0.365, P = 0.008);td阳性(HR = 0.401, P = 0.026)。td阳性患者辅助化疗的中位OS从22.3-51.3个月增加(P = 0.019)。bvi阴性亚组的TD阳性预后较差(OS: HR = 3.840, 95% CI: 2.058-7.166, P < 0.001;无进展生存期(PFS): HR = 2.950, 95% CI: 1.550-5.617, P = 0.002)。结论:胰胆特征和BVI是AAC的高危病理特征。TD状态确定高风险队列,从而实现术后风险分层治疗策略。在胰胆管特征或BVI阴性的患者中,TD阳性预测生存率明显较差。
{"title":"Identifying occult high-risk features and stratified management strategies following curative resection for ampullary adenocarcinoma.","authors":"Xiaoqing Ma, Chenyang Meng, Xuejing Shi, Zhaoyu Zhang, Qiuli Li, Hongwei Wang, Yuexiang Liang, Song Gao, Xiuchao Wang, Chuntao Gao, Jian Wang, Weidong Ma, Yukuan Feng, Shuo Li, Xingyun Chen, Wei Li, Shangheng Shi, Tianxing Zhou, Jun Yu, Jihui Hao","doi":"10.20892/j.issn.2095-3941.2025.0181","DOIUrl":"10.20892/j.issn.2095-3941.2025.0181","url":null,"abstract":"<p><strong>Objective: </strong>The aim of the current study was to identify independent prognostic factors, evaluate differential adjuvant chemotherapy efficacy across clinicopathologic subgroups, and define adjuvant chemotherapy-sensitive populations.</p><p><strong>Methods: </strong>A retrospective analysis of 168 AAC patients undergoing curative pancreaticoduodenectomy (2011-2020) was performed. Cases were classified into intestinal (28.0%), pancreatobiliary (30.4%), and mixed subtypes (18.5%) per NCCN (v2.2025) criteria. Independent prognostic factors for AAC patients were identified through uni- and multi-variable Cox proportional hazards modeling and subgroup analyses were stratified by age range, gender, differentiation, T stage, N stage, BVI, TDs, and PNI.</p><p><strong>Results: </strong>The pancreatobiliary signature (HR = 2.884, <i>P</i> < 0.001) and BVI (HR = 2.330, <i>P</i> = 0.001) were independent poor prognostic factors. Adjuvant chemotherapy improved overall survival (OS) in the following AAC patients: T3-T4 stage (HR = 0.485, <i>P</i> = 0.050); N1-N2 stage (HR = 0.365, <i>P</i> = 0.008); and TD-positive (HR = 0.401, <i>P</i> = 0.026). The median OS increased from 22.3-51.3 months with adjuvant chemotherapy in TD-positive patients (<i>P</i> = 0.019). TD positivity conferred a worse prognosis in BVI-negative subgroups (OS: HR = 3.840, 95% CI: 2.058-7.166, <i>P</i> < 0.001; and progression-free survival (PFS): HR = 2.950, 95% CI: 1.550-5.617, <i>P</i> = 0.002).</p><p><strong>Conclusions: </strong>The pancreatobiliary signature and BVI constitute critical high-risk pathologic features in AAC. TD status identified high-risk cohorts, thus enabling postoperative risk-stratified treatment strategies. In patients negative for pancreatobiliary signature or BVI, TD positivity predicted significantly worse survival.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"22 10","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12533976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145312426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chromatin relaxation dynamics and histone PTMs in the early DNA damage response. 早期DNA损伤反应中的染色质松弛动力学和组蛋白ptm。
IF 8.4 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-10-09 DOI: 10.20892/j.issn.2095-3941.2025.0369
Jinqin Qian, Zhongyi Xie, Liqun Zhou, Wei-Guo Zhu
{"title":"Chromatin relaxation dynamics and histone PTMs in the early DNA damage response.","authors":"Jinqin Qian, Zhongyi Xie, Liqun Zhou, Wei-Guo Zhu","doi":"10.20892/j.issn.2095-3941.2025.0369","DOIUrl":"10.20892/j.issn.2095-3941.2025.0369","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12624809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145279025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IL-17A blockade alleviates immune checkpoint inhibitor-associated psoriasiform rash: preclinical and clinical responses. IL-17A阻断缓解免疫检查点抑制剂相关银屑病样皮疹:临床前和临床反应
IF 8.4 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-10-09 DOI: 10.20892/j.issn.2095-3941.2025.0344
Yuli Ruan, Mengde Shi, Yue Ma, Bojun Wang, Ming Ma, Tianjiao Dang, Yanqiao Zhang, Chao Liu
{"title":"IL-17A blockade alleviates immune checkpoint inhibitor-associated psoriasiform rash: preclinical and clinical responses.","authors":"Yuli Ruan, Mengde Shi, Yue Ma, Bojun Wang, Ming Ma, Tianjiao Dang, Yanqiao Zhang, Chao Liu","doi":"10.20892/j.issn.2095-3941.2025.0344","DOIUrl":"10.20892/j.issn.2095-3941.2025.0344","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12624807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145279028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modeling cervical cancer elimination: a pathway to inform policy decisions. 模拟消除子宫颈癌:为政策决策提供信息的途径。
IF 8.4 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-10-06 DOI: 10.20892/j.issn.2095-3941.2025.0387
Panliang Zhong, Li Zhang, Fanghui Zhao
{"title":"Modeling cervical cancer elimination: a pathway to inform policy decisions.","authors":"Panliang Zhong, Li Zhang, Fanghui Zhao","doi":"10.20892/j.issn.2095-3941.2025.0387","DOIUrl":"10.20892/j.issn.2095-3941.2025.0387","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"22 9","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accelerating the elimination of global cervical cancer through intelligent training for colposcopy. 通过阴道镜智能培训加速全球消除宫颈癌。
IF 8.4 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-10-06 DOI: 10.20892/j.issn.2095-3941.2025.0403
Mingyang Chen, Jiayi Ma, Yijin Wu, Haiyan Hu, Xiaoli Cui, Maria José Gonzalez Mendez, Roberto Altamirano, Nomin-Erdene Tsogtgerel, Erdenejargal Ayush, Lingqing Qiu, Xinhua Jia, José Luis López Velázquez, Sulaiya Husaiyin, Aiyuan Wu, Man Tat Alexander Ng, Youlin Qiao

Objective: Cervical cancer remains a global health challenge with substantial disparities between countries. High-quality colposcopy is essential for cervical cancer prevention, yet training opportunities remain inadequate worldwide. We developed the Intelligent Digital Education Tool for Colposcopy (iDECO) to address training gaps and evaluated the effect across diverse international settings.

Methods: Six pre-post interventional training programmes were conducted in China, Mexico, and Mongolia from December 2024 to May 2025. A total of 369 trainees from 87 centers participated in a 3-week online training programme using iDECO, a bilingual web-based platform featuring authentic colposcopy cases, gamified learning pathways, and personalized analytics. The primary outcomes included colposcopy competence in general assessment, colposcopic findings, diagnostic accuracy, and management decisions. The secondary outcomes focused on participant feedback and satisfaction.

Results: Of 369 participants who completed pretests, 333 (90.24%) completed post-training assessments. Significant improvements were observed across all competency domains. Diagnostic accuracy increased with an odds ratio (OR) of 1.72 (95% CI: 1.60-1.86) with the greatest gains in high-grade lesion identification [OR = 2.27 (95% CI: 1.94-2.64)]. Squamocolumnar junction visibility and transformation zone type assessments improved with ORs of 1.41 (95% CI: 1.31-1.51) and 1.87 (95% CI: 1.73-2.01), respectively. Biopsy decision-making accuracy also showed significant improvement [OR = 2.09 (95% CI: 1.91-2.29)]. International participants showed lower baseline performance but achieved the greatest improvements. Greater than 85% of participants rated the training highly satisfactory and 83.56% preferred intelligent training over traditional methods.

Conclusions: iDECO-based training significantly improved colposcopy competence across diverse international settings with high user satisfaction. These findings support the potential for worldwide implementation of intelligent digital training tools to address colposcopy training gaps and contribute to the elimination of cervical cancer.

目的:宫颈癌仍然是全球健康挑战,各国之间存在巨大差异。高质量的阴道镜检查对宫颈癌的预防至关重要,但培训机会在世界范围内仍然不足。我们开发了智能数字阴道镜教育工具(iDECO),以解决培训差距,并评估了在不同国际环境下的效果。方法:于2024年12月至2025年5月在中国、墨西哥和蒙古开展了6个干预前后培训项目。共有来自87个中心的369名学员参加了为期三周的在线培训项目,该项目使用的是基于双语网络平台ideeco,该平台具有真实的阴道镜检查案例、游戏化学习途径和个性化分析。主要结果包括阴道镜检查的一般评估能力、阴道镜检查结果、诊断准确性和管理决策。次要结果关注参与者反馈和满意度。结果:369名参与者完成了前测,333名(90.24%)完成了训练后评估。在所有能力领域都观察到显著的改进。诊断准确性提高,优势比(OR)为1.72 (95% CI: 1.60-1.86),其中鉴别高级别病变的优势比(OR = 2.27 (95% CI: 1.94-2.64)最大。鳞状柱结可见性和转化区类型评估的or值分别为1.41 (95% CI: 1.31-1.51)和1.87 (95% CI: 1.73-2.01)。活检决策准确性也有显著提高[OR = 2.09 (95% CI: 1.91-2.29)]。国际参与者表现出较低的基准表现,但取得了最大的进步。超过85%的参与者对培训非常满意,83.56%的参与者更喜欢智能培训而不是传统方法。结论:基于ideco的培训显著提高了不同国际环境下的阴道镜检查能力,用户满意度高。这些发现支持了智能数字培训工具在全球范围内实施的潜力,以解决阴道镜检查培训差距,并有助于消除宫颈癌。
{"title":"Accelerating the elimination of global cervical cancer through intelligent training for colposcopy.","authors":"Mingyang Chen, Jiayi Ma, Yijin Wu, Haiyan Hu, Xiaoli Cui, Maria José Gonzalez Mendez, Roberto Altamirano, Nomin-Erdene Tsogtgerel, Erdenejargal Ayush, Lingqing Qiu, Xinhua Jia, José Luis López Velázquez, Sulaiya Husaiyin, Aiyuan Wu, Man Tat Alexander Ng, Youlin Qiao","doi":"10.20892/j.issn.2095-3941.2025.0403","DOIUrl":"10.20892/j.issn.2095-3941.2025.0403","url":null,"abstract":"<p><strong>Objective: </strong>Cervical cancer remains a global health challenge with substantial disparities between countries. High-quality colposcopy is essential for cervical cancer prevention, yet training opportunities remain inadequate worldwide. We developed the Intelligent Digital Education Tool for Colposcopy (iDECO) to address training gaps and evaluated the effect across diverse international settings.</p><p><strong>Methods: </strong>Six pre-post interventional training programmes were conducted in China, Mexico, and Mongolia from December 2024 to May 2025. A total of 369 trainees from 87 centers participated in a 3-week online training programme using iDECO, a bilingual web-based platform featuring authentic colposcopy cases, gamified learning pathways, and personalized analytics. The primary outcomes included colposcopy competence in general assessment, colposcopic findings, diagnostic accuracy, and management decisions. The secondary outcomes focused on participant feedback and satisfaction.</p><p><strong>Results: </strong>Of 369 participants who completed pretests, 333 (90.24%) completed post-training assessments. Significant improvements were observed across all competency domains. Diagnostic accuracy increased with an odds ratio (OR) of 1.72 (95% CI: 1.60-1.86) with the greatest gains in high-grade lesion identification [OR = 2.27 (95% CI: 1.94-2.64)]. Squamocolumnar junction visibility and transformation zone type assessments improved with ORs of 1.41 (95% CI: 1.31-1.51) and 1.87 (95% CI: 1.73-2.01), respectively. Biopsy decision-making accuracy also showed significant improvement [OR = 2.09 (95% CI: 1.91-2.29)]. International participants showed lower baseline performance but achieved the greatest improvements. Greater than 85% of participants rated the training highly satisfactory and 83.56% preferred intelligent training over traditional methods.</p><p><strong>Conclusions: </strong>iDECO-based training significantly improved colposcopy competence across diverse international settings with high user satisfaction. These findings support the potential for worldwide implementation of intelligent digital training tools to address colposcopy training gaps and contribute to the elimination of cervical cancer.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"22 9","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145237837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Biology & Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1